Dyax (DYAX) Said Study Shows DX-88 Provides Rapid and Sustained Relief for Hereditary Angioedema
Dyax Corp. (Nasdaq: DYAX) announced presentation of an integrated analysis of the two DX-88 Phase 3 studies demonstrating that treatment with DX-88 (ecallantide) provided clinically meaningful, rapid and sustained relief of symptoms in acute attacks of hereditary angioedema (HAE), when compared to placebo.
Statistically significant improvement in symptoms was demonstrated with DX-88 at four hours after treatment and persisted throughout the 24-hour period of evaluation. The integrated analysis also demonstrated that DX-88 was efficacious in treating all acute attack locations (laryngeal, abdominal, peripheral) and was well tolerated, with no treatment-related serious adverse events.
More from Release
Statistically significant improvement in symptoms was demonstrated with DX-88 at four hours after treatment and persisted throughout the 24-hour period of evaluation. The integrated analysis also demonstrated that DX-88 was efficacious in treating all acute attack locations (laryngeal, abdominal, peripheral) and was well tolerated, with no treatment-related serious adverse events.
More from Release
You May Also Be Interested In
- Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- Nymox Pharmaceutical (NYMX) Reports Statistically Significant Data for NX-1207 in BPH
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
